Affiliation:
1. VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ, ECZACILIK TEMEL BİLİMLERİ BÖLÜMÜ, FARMASOTİK MİKROBİYOLOJİ ANABİLİM DALI
Abstract
Objective: The emergence of antibiotic resistance in Pseudomonas aeruginosa and Acinetobacter baumanii isolates poses serious risks to public health. Our study aimed to investigate the presence of colistin resistance and mcr-1 gene positivity in these isolates.
Material and Method: Culture, biochemical tests, antibiotic susceptibility tests, and molecular tests were used to isolate and identify P. aeruginosa and A. baumanii strains.
Result and Discussion: A sum of 156 clinical isolates of Pseudomonas aeruginosa (n = 89) and Acinetobacter baumannii (n = 67) were obtained using the 550 clinical samples collected in one year from the largest hospital in Van, Turkey. The results of antibiotic susceptibility tests showed that approximately 82.8% of P. aeruginosa and 94.6% of A. baumannii strains were multidrug-resistant (MDR). Colistin resistance was detected in 11.23% (10/89) of P. aeruginosa isolates and 11.94% (8/67) of A. baumannii isolates using agar dilution and microdilution methods. Out of the 18 colistin-resistant isolates, the mcr-1 gene was detected in three P. aeruginosa and two A. baumannii strains. The detection of plasmid-mediated colistin resistance in P. aeruginosa and A. baumannii is of great concern due to the high potential for colistin resistance to spread in clinical settings. Understanding the unique circumstances of worldwide colistin resistance can be facilitated by promoting the creation of quick processes for identifying colistin resistance profiles and putting them into practice in hospital laboratories. Colistin and carbapenem treatment are two effective ways to treat emerging resistant super-microbes and slow down the emergence of resistance.
Funder
IT WAS NOT SUPPORTED BY ANY INSTITUTION.
Publisher
Ankara Universitesi Eczacilik Fakultesi Dergisi
Reference39 articles.
1. 1. Bialvaei, A.Z., and Samadi K.H. (2015). Colistin, mechanisms and prevalence of resistance. Current Medical Research and Opinion, 31(4), 707-721. [CrossRef]
2. 2. Vogel, G. (2017) Meet WHO’s dirty dozen: The 12 bacteria for which new drugs are most urgently needed. Science. Availible from: https://www.sciencemag.org/news/2017/02/meet- ho-s-dirtydozen- 12-bacteria-which-new-drugs-are-most-urgently-needed. [CrossRef]
3. 3. Willyard, C. (2017). Drug-resistant bacteria ranked. Nature, 543(7643), 15. [CrossRef]
4. 4. Vincent, J.L., Rello, J., Marshall, J., Silva, E., Anzueto, A., Martin, C.D., Epic II Group of Investigators. (2009). International study of the prevalence and outcomes of infection in intensive care units. JAMA, 302(21), 2323-2329. [CrossRef]
5. 5. Wright, H., Bonomo, R.A., Paterson, D.L. (2017). New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn? Clinical Microbiology and Infection, 23(10), 704-712. [CrossRef]